TCGA-CV-5435-01A-01R-1686-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.529452055
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- HEDGEHOG_SIGNALING+0.480
- MYOGENESIS+0.420
- WNT_BETA_CATENIN_SIGNALING+0.350
- MTORC1_SIGNALING+0.270
- MITOTIC_SPINDLE+0.260
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.250
- ANGIOGENESIS+0.190
- G2M_CHECKPOINT+0.190
- UV_RESPONSE_DN+0.190
- GLYCOLYSIS+0.180
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.560
- INTERFERON_GAMMA_RESPONSE-0.500
- ALLOGRAFT_REJECTION-0.450
- OXIDATIVE_PHOSPHORYLATION-0.400
- IL6_JAK_STAT3_SIGNALING-0.350
- INFLAMMATORY_RESPONSE-0.290
- COMPLEMENT-0.260
- DNA_REPAIR-0.210
- APOPTOSIS-0.190
- COAGULATION-0.190
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-AR-A0TP-01A-11R-A084-07 | — | E | 0.825 |
| 2 | TCGA-51-4081-01A-01R-1100-07 | — | cohortSQ2 | 0.814 |
| 3 | C3N-03662 | — | cohortSQ2 | 0.810 |
| 4 | 20110025.TNBC | — | E | 0.777 |
| 5 | SRR5903551 | — | cohortA1 | 0.770 |
| 6 | TCGA-D8-A1XD-01A-11R-A14D-07 | — | B | 0.769 |
| 7 | TCGA-CN-6024-01A-11R-1686-07 | — | — | 0.766 |
| 8 | SRR15030856 | — | — | 0.759 |
| 9 | 20120162.TNBC | — | E | 0.755 |
| 10 | TCGA-AN-A0FX-01A-11R-A034-07 | — | E | 0.752 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| HEDGEHOG_SIGNALING | 0.480 | Inavolisib | — uncovered |
| MYOGENESIS | 0.420 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.350 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.270 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.260 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.250 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.190 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.190 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.190 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.180 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.180 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.170 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.150 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.140 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.130 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.120 | Inavolisib | — uncovered |
| HYPOXIA | 0.090 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.090 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.090 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.070 | Inavolisib | — uncovered |